Hwail Pharmaceutical Overview
- Year Founded
-
1974
- Status
-
Public
- Employees
-
161
- Stock Symbol
-
061250
- Investments
-
5
- Share Price
-
$4.08
- (As of Friday Closing)
Hwail Pharmaceutical General Information
Description
Hwail Pharm Co Ltd is engaged in manufacturing and distribution of raw materials used in pharmaceutical production. Its products include antitussive expectorants, spasmolytic, stomach function modifier, anti-inflammatory, and others.
Contact Information
Website
www.hwail.comCorporate Office
- 241, Sandan-ro
- Pyeongtaek, Gyeonggi
- South Korea
Corporate Office
- 241, Sandan-ro
- Pyeongtaek, Gyeonggi
- South Korea
Hwail Pharmaceutical Timeline
Hwail Pharmaceutical Stock Performance
As of 13-Nov-2026, Hwail Pharmaceutical’s stock price is $4.08. Its current market cap is $34.4M with 8.41M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $4.08 | $4.04 | $3.67 - $8.47 | $34.4M | 8.41M | 24.7K | $0.08 |
Hwail Pharmaceutical Financials Summary
As of 31-Mar-2026, Hwail Pharmaceutical has a trailing 12-month revenue of $66.1M.
|
In Thousands, USD |
TTM 31-Mar-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 1,815 | 13,566 | 28,508 | 63,595 |
| Revenue | 66,118 | 70,842 | 87,775 | 93,725 |
| EBITDA | 802 | 239 | 5,769 | 3,349 |
| Net Income | 704 | (164) | 4,750 | 2,955 |
| Total Assets | 141,533 | 148,027 | 146,377 | 144,335 |
| Total Debt | 233 | 233 | 2,280 | 1,815 |
Hwail Pharmaceutical Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Hwail Pharmaceutical Patents
Hwail Pharmaceutical Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025263998-A1 | Novel salt of tegoprazan and method for preparing same | Pending | 20-Jun-2024 | ||
| WO-2015080435-A1 | Method for preparing 4-(3-(3-fluorophenyl)-5,5-dimethyl-4-oxo-4,5-dihydrofuran-2-yl)benzenesulfonamide | Inactive | 26-Nov-2013 | ||
| EP-2398450-A2 | Aqueous nanoemulsion composition containing conjugated linoleic acid | Active | 20-Feb-2009 | ||
| EP-2398450-A4 | Aqueous nanoemulsion composition containing conjugated linoleic acid | Active | 20-Feb-2009 | ||
| EP-2398450-B1 | Aqueous nanoemulsion composition containing conjugated linoleic acid | Active | 20-Feb-2009 | A61K8/06 |
Hwail Pharmaceutical Signals
Hwail Pharmaceutical Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Hwail Pharmaceutical Investments & Acquisitions (5)
Hwail Pharmaceutical’s most recent deal was a Corporate Asset Purchase with Ecovolt (Land and Buildings at 241 Sandan-ro in Pyeongtaek, South Korea) for . The deal was made on 06-Dec-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Ecovolt (Land and Buildings at 241 Sandan-ro in Pyeongtaek, South Korea) | 06-Dec-2024 | Corporate Asset Purchase | Buildings and Property | ||
| Dynamic solution (Therapeutic Devices) | 09-Apr-2024 | PIPE | Therapeutic Devices | ||
| PanGen Biotech | 27-Mar-2024 | PIPE | Pharmaceuticals | ||
| CTCBio | 01-Apr-2021 | PIPE | Pharmaceuticals | ||
| HuonsLifeSciences | 07-Dec-2015 | Merger/Acquisition | Pharmaceuticals |
Hwail Pharmaceutical ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
Hwail Pharmaceutical Exits (1)
Hwail Pharmaceutical’s most recent exit was on 07-Dec-2015 from HuonsLifeSciences. The exit was categorized as with 2 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| HuonsLifeSciences | 07-Dec-2015 | Completed |
|
Hwail Pharmaceutical FAQs
-
When was Hwail Pharmaceutical founded?
Hwail Pharmaceutical was founded in 1974.
-
Where is Hwail Pharmaceutical headquartered?
Hwail Pharmaceutical is headquartered in Pyeongtaek, South Korea.
-
What is the size of Hwail Pharmaceutical?
Hwail Pharmaceutical has 161 total employees.
-
What industry is Hwail Pharmaceutical in?
Hwail Pharmaceutical’s primary industry is Other Pharmaceuticals and Biotechnology.
-
Is Hwail Pharmaceutical a private or public company?
Hwail Pharmaceutical is a Public company.
-
What is Hwail Pharmaceutical’s stock symbol?
The ticker symbol for Hwail Pharmaceutical is 061250.
-
What is the current stock price of Hwail Pharmaceutical?
As of 13-Nov-2026 the stock price of Hwail Pharmaceutical is $4.08.
-
What is the current market cap of Hwail Pharmaceutical?
The current market capitalization of Hwail Pharmaceutical is $34.4M.
-
What is Hwail Pharmaceutical’s current revenue?
The trailing twelve month revenue for Hwail Pharmaceutical is $66.1M.
-
What is Hwail Pharmaceutical’s annual earnings per share (EPS)?
Hwail Pharmaceutical’s EPS for 12 months was $0.08.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process